Aroa Biosurgery Limited is a regenerative medicine and medical device company specializing in products for wound healing and soft tissue repair. Utilizing proprietary extracellular matrix (ECM) technologies derived from ovine sources, Aroa Biosurgery designs, develops, and manufactures bioscaffolds and implantable devices intended to support tissue regeneration in complex wounds, surgical reconstruction, and various clinical settings. Key product lines include Endoform and Myriad, which are used to treat acute and chronic wounds, facilitate soft tissue reinforcement, and support advanced surgical procedures such as abdominal wall reconstruction and hernia repair. Based in Auckland, New Zealand, Aroa Biosurgery serves hospitals and clinicians across North America, Europe, and globally, delivering innovations backed by robust clinical evidence and a commitment to scalable, high-quality manufacturing. By focusing on functional healing outcomes and evidence-based development, Aroa Biosurgery plays a pivotal role in advancing regenerative therapies and providing clinicians with solutions for challenging medical conditions in the healthcare and biotechnology sectors.